CMA fines pharmaceutical company more than £100m

02 Aug 2021

There has been a recent spate of companies buying up the exclusive rights to sell drugs and then marking up the prices; other companies have got together and agreed to carve up markets in drugs and make supernormal profits. In some cases, the NHS has seen an increase in drug prices by thousands of percent.
The Competition and Markets Authority (CMA) has reacted in a series of cases targeting what it describes as ‘unfair inflation’.
In the most recent instance, the CMA has fined Advanz and its private equity owners over £100m for inflating the price of drugs causing losses to the NHS and the tax payer.
Following an investigation the CMA found that between 2009 and 2017 Advanz charged ‘excessive and unfair prices’ for supplying liothyronine tablets which are used to treat thyroid conditions; prices rose by up to 6,000% during the period, whilst production costs remained stable.
The increased spending on the drug (from £600k in 2006 to £30m in 2016) led the NHS to put the drug on the ‘drop list, preventing GPs from prescribing liothyronine tablets and denying many patients the most effective treatment for their condition. The CMA’s decision will make it easier for the NHS to pursue compensation should they choose to.
This decision comes as the CMA is undertaking a number of investigations into pharmaceutical companies and pricing practices. Just last month the authority fined a number of companies £260m for competition law breaches resulting in inflated costs for generic hydrocortisone tablets over the course of 10 years.
The CMA’s crackdown on pharmaceutical companies should lead to the fair pricing of drugs for the NHS and private consumers alike so that patients can continue to receive the treatment they need.
Those who would abuse market dominance or seek to carve up markets should be aware that the CMA is being increasingly aggressive – and not just in respect of Big Pharma.

Further reading

Controversy surrounds remote Will witnessing amidst rising inheritance disputes

The once lawful practice of remotely witnessing Wills is to be removed due to a surge in contentious inheritance disputes
Read more Read

Changes at Companies House The Economic Crime and Corporate Transparency Act

The Economic Crime and Corporate Transparency Act 2023 (the “Act”) aims to deliver a range of reforms to tackle economic crime and improve transparency over corporate entities.
Read more Read

The Body Shop; once a pioneering ethical brand, now in administration

Frank Bouette, Restructuring and Insolvency Partner, provides commentary on the Body Shop Administration and the fragility of the high street
Read more Read

DMH Stallard advises on St Barnabas and Martlets Hospice merger

The merger is described by St Barnabas as a move that ‘aims to create a stronger, more sustainable and comprehensive hospice care organisation...'
Read more Read
  • Brighton - Jubilee St

    1 Jubilee Street


    East Sussex

    BN1 1GE

  • Brighton - Old Steine

    47 Old Steine


    East Sussex

    BN1 1NW

  • Gatwick

    Griffin House

    135 High Street


    West Sussex

    RH10 1DQ

  • Guildford

    Wonersh House

    The Guildway

    Old Portsmouth Road



    GU3 1LR

  • Hassocks

    32 Keymer Road


    West Sussex

    BN6 8AL

  • Horsham

    3rd Floor

    Afon Building

    Worthing Road


    West Sussex

    RH12 1TL

  • London

    6 New Street Square

    New Fetter Lane


    EC4A 3BF

  • Make an enquiry

    Make an enquiry


    Or head to our Contact us page